References
- Jain N, O’Brien S. Initial treatment of CLL: integrating biology and functional status. Blood 2015;126:463–470.
- Sciumè M, Vincenti D, Reda G, et al. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: genetic profile and long-term outcome from a single center experience. Am J Hematol 2015;July 22 [Epub ahead of print]
- Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110–2118.
- Zent CS, Call TG, Bowen DA, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and PGG beta glucan is well tolerated and achieves high complete remission rates. Leuk Lymphoma 2015;56:2373–2378.
- Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The Oncologist 2008;13:954–966.
- Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002:99;1038–1043.
- Zent CS, Secreto CR, LaPlant BR, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849–1856.
- Pallasch CP, Leskov I, Braun CJ, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014;156: 590–602.
- Roit FD, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2014;100:77–86.
- Modak S, Koehne G, Vickers A, et al. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-D- β-glucan. Leuk Res 2005;29:679–683.
- Vannucci L, Krizan J, Sima P, et al. Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol 2013;43:357–364.